CCL11 and secondary progressive multiple sclerosis: The only study we were able to identify regarding the subject is from 2020 by Huang et al. They found Eotaxin-1 (CCL11) to be increased in both the CSF and the plasma of SPMS patients as compared to RRMS patients [175].